LETYBO
Growthletibotulinumtoxina-wlbg
BLAINTRAMUSCULARPOWDER, FOR SOLUTION
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LETYBO (letibotulinumtoxina-wlbg) is acetylcholine release inhibitors [moa]. First approved in 2024.
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LETYBO (letibotulinumtoxina-wlbg) is a novel acetylcholine release inhibitor administered intramuscularly as a powder for solution. It represents a new botulinum toxin-based biologic that blocks acetylcholine release at the neuromuscular junction. The specific indications for this product have not yet been publicly disclosed.
Growth
Early-stage growth product with moderate competitive pressure (30%) suggests emerging market opportunity and potential for team expansion in commercial and medical affairs roles.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LETYBO represents an early-growth opportunity in a competitive specialty market with emerging safety and efficacy data that will drive strategic positioning. Working on this product offers exposure to biologic commercialization and competitive market dynamics, though limited current job openings suggest team is still being built.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.